Natera company profile
Company profile
Natera has 6,135 employees and is headquartered in Austin, United States.
Based in Austin, Texas, Natera was founded in 2003 and develops and commercializes molecular testing services. Its portfolio includes Signatera, a personalized ctDNA blood test used for MRD assessment and early recurrence monitoring, alongside Panorama, a non-invasive prenatal test, and Prospera, a test for active rejection in patients with solid organ transplants. Its customers include independent and reference laboratories, medical centers, physician practices, research laboratories and pharmaceutical companies, reached through a direct sales force, laboratory distribution partners and Constellation licensees. The company was formerly known as Gene Security Network until it changed its name to Natera in January 2012.
In the fiscal year ended December 2025, Natera reported revenue of $2.3 billion, up 35.9% from the previous year, and a net loss of $208.2 million. The United States accounted for 98.2% of revenue that year. The company had 6,135 employees.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Headquarters
- 13011 McCallen Pass, 78753, Austin
- Employees
- 6,135
- Chief executive
- Steven Chapman
- Founded
- 2003
- Fiscal year
- January - December
- Listing
- NTRA · NASDAQ
- Currency
- USD
- ISIN
- US6323071042
- Website
- natera.com
Natera and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| NateraNTRA | United States | $46.27B | 6,135 | -8.5% | — |
| IQVIA HoldingsIQV | United States | $43.69B | 95,000 | 13.9% | 32.3 |
| Agilent TechnologiesA | United States | $49.04B | 18,200 | 24.5% | 34.3 |
| IDEXX LaboratoriesIDXX | United States | $55.48B | 11,000 | 32.5% | 47.0 |
| Mettler-Toledo InternationalMTD | United States | $34.59B | 16,600 | 27.8% | 37.7 |
| IlluminaILMN | United States | $31.3B | 8,600 | 19.1% | 36.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
